Abstract: This invention is related to the field of hypercholesterolemia. In particular, the invention provides compositions and methods to modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9 using synthetic ligands and/or synthetic ligand derivative sequences of 3-8 amino acids ranging between 350-2,000 Da. Altering the conformation of PCSK9 affects the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for ligands which can raise LDL levels.

Abstract: An apparatus and method wherein the apparatus includes a bendable display; a substrate configured to support the bendable display wherein the substrate includes at least one bendable portion configured to enable the bendable display to be moved between an open configuration and a closed configuration; and a support structure provided adjacent to the bendable portion of the substrate configured to provide a rigid support for the bendable portion of the substrate, at least, when the display is in the closed configuration.

Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof, wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

Abstract: According to various, but not necessarily all examples of the disclosure, there may be provided an apparatus and method wherein the apparatus comprises: a substrate configured to support a bendable display wherein the substrate comprises at least one bendable portion configured to enable the substrate to be moved between an open configuration and a closed configuration; and wherein the at least one bendable portion comprises a plurality of rod members and the rod members comprise interlocking portions wherein the interlocking portions comprise a projection configured to fit into a corresponding recess on an adjacent rod member so as to restrict relative movement of the rod members when the substrate is in the closed configuration.

Abstract: An apparatus and method wherein the apparatus includes a bendable display; a substrate configured to support the bendable display wherein the substrate includes at least one bendable portion configured to enable the bendable display to be moved between an open configuration and a closed configuration; and a support structure provided adjacent to the bendable portion of the substrate configured to provide a rigid support for the bendable portion of the substrate, at least, when the display is in the closed configuration.

Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

Abstract: This invention is related to the field of hypercholesterolemia. In particular, the invention provides compositions and methods to modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9 using synthetic ligands and/or synthetic ligand derivative sequences of 3-8 amino acids ranging between 350-2,000 Da. Altering the conformation of PCSK9 affects the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for ligands which can raise LDL levels.

Abstract: According to various, but not necessarily all examples of the disclosure, there may be provided an apparatus and method wherein the apparatus comprises: a substrate configured to support a bendable display wherein the substrate comprises at least one bendable portion configured to enable the substrate to be moved between an open configuration and a closed configuration; and wherein the at least one bendable portion comprises a plurality of rod members and the rod members comprise interlocking portions wherein the interlocking portions comprise a projection configured to fit into a corresponding recess on an adjacent rod member so as to restrict relative movement of the rod members when the substrate is in the closed configuration.

Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

Abstract: Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

Abstract: Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

Abstract: Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

Abstract: According to various, but not necessarily all examples of the disclosure, there may be provided an apparatus and method wherein the apparatus comprises: a substrate configured to support a bendable display wherein the substrate comprises at least one bendable portion configured to enable the substrate to be moved between an open configuration and a closed configuration; and wherein the at least one bendable portion comprises a plurality of rod members and the rod members comprise interlocking portions wherein the interlocking portions comprise a projection configured to fit into a corresponding recess on an adjacent rod member so as to restrict relative movement of the rod members when the substrate is in the closed configuration.